The latest in the long spree of partnerships to pair PD1 and PD-L1 inhibitors with other approaches to boost efficacy has arrived with a deal between Roche’s…

The latest deal on the CAR-T front is between Juno partner Fate Therapeutics and the Memorial Sloan Kettering Cancer Center.

Amgen is working on sorting out its immuno-oncology strategy. It’s taken another step in that direction in a new deal with Boehringer Ingelheim to gain global…

BioLineRx has teamed up with I-Bridge Capital to set up a Chinese drug development joint venture, iPharma.

Johnson & Johnson ($JNJ) has partnered with a microbiome startup in its JLABS San Diego incubator to develop treatments for inflammatory skin diseases.

A snapshot survey of biotech chiefs during the second quarter has shown that their confidence to be able to raise funds has doubled since Q1, but they are a…

Bristol-Myers Squibb is adding to an existing partnership with Bavarian Nordic to start a Phase II combo trial of Opdivo with Bavarian’s cancer vaccine CV301…

Preclinical microcap Eleven Biotherapeutics hopes to press the reset button by refocusing on a Roche deal that could continue to offer infusions of cash, or be…